Acute Myeloid Leukemia and Myelodysplastic Syndromes | Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes

published 5 months ago by Dr Neil Love

Featuring perspectives from Drs Mikkael A Sekeres and Richard M Stone on the following topics: Management of Acute Myeloid Leukemia (AML) Introduction (0:00) Venetoclax combinations — Azacitidine, LDAC (2:02) FLT3 inhibitors — Midostaurin, gilteritinib (20:24) IDH inhibitors — Ivosidenib, enasidenib (26:00) Oral azacitidine (CC-486) (31:14) Secondary AML — CPX-351 (36:28) Treatment Strategies for Myelodysplastic Syndromes (MDS) Lower-risk MDS — Luspatercept, imetelstat (38:45) Higher-risk MDS — Decitabine + cedazuridine, azacitidine + venetoclax, magrolimab, APR-246, pevonedistat (44:06) CME information and select publications

more episodes from Research To Practice | Oncology Videos